FindTrial
Sign In

Validation for clinical utility of biomarkers for the early diagnosis of breast cancer

Validation for clinical utility of biomarkers for the early diagnosis of breast cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0005212
Enrollment
496
Registered
2020-07-09
Start date
2018-07-26
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Seoul National University Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: - Breast Cancer patients - Women over 18 - Patients diagnosed with breast cancer by biopsy before treatment (patients before surgery and neoadjuvant chemotherapy)

Exclusion criteria

Exclusion criteria: - Carcinoma in situ - Recurrent breast cancer patient - Any person diagnosed with another cancer within five years. - Patients who started treatment after being diagnosed with breast cancer

Design outcomes

Primary

MeasureTime frame
Prospective demonstrate the diagnostic validity of blood based biomarkers for early diagnosis of breast cancer—

Secondary

MeasureTime frame
Comparison of changes in blood-based biomarkers before and after breast cancer treatment -To determine if there is any usefulness to follow up—

Countries

Korea, Republic of

Contacts

Public ContactYumi Kim

Seoul National University Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026